New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •New every week: podcasts, research & peptide news •
← All articles

Explainer · 14 Nov 2026 · 7 min

Retatrutide explained: the triple agonist everyone is talking about

What it is, how it differs from earlier GLP-1 peptides, and where the research stands right now.

Retatrutide is an investigational peptide that acts on three hormone receptors at once: GLP-1, GIP and glucagon. Earlier compounds targeted one or two of these.

Interest exploded after phase 2 results were published, showing larger effects on body weight in study participants than earlier single-target compounds. Phase 3 trials are ongoing.

Important: retatrutide is not an approved medicine. Research-grade material is sold for laboratory research only.

Exclusive for PeptideNews readers

Get exclusive access to a trusted source of RUO peptides

As a research site, we can give you access to a supplier that meets the standards we write about.

  • 60-day money-back guarantee
  • Temperature-protected shipping
  • Produced in the EU
  • Third-party lab tested
  • Traceable testing
  • 99% purity
  • Delivery in 2–5 days across the EU

For research use only (RUO). Not for human consumption.